DRMA: מחיר למכירות Dermata
The price-to-sales ratio demonstrates the market valuation of Dermata Therapeutics (DRMA), where the value is fixed at 46.70. The scientific team is developing a unique drug delivery platform to combat rosacea and acne. Dermata Therapeutics (DRMA) is creating innovative topical agents based on freshwater sponges, currently undergoing FDA reviews. Patents for a mechanical therapy method provide a competitive advantage, determining the future profitability of the business.
Dermata (DRMA) - פילוחי מדדים ודוחות פיננסיים
Dermata Therapeutics' reputation for developing safe acne and rosacea treatments drives high brand equity, which investors evaluate via the price-to-sales ratio. This metric measures the cost per unit of revenue, allowing the P/S levels on the chart to determine the asset's degree of overvaluation and identify the exhaustion of business growth drivers in a timely manner.
